Clinical trial · Interventional
The Efficacy and Safety of Nerve-sparing Radical Hysterectomy in Cervical Cancer
NCT01893333CI-TRIAL-00027921NSRHCXCAunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To develope nerve sparing radical hysterectomy for treatment of cervical cancer to minimize the complication of radical hysterectomy and to maximize quality of life and to evaluate the feasibility and efficacy by prospective randomized trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nerve sparing radical hysterectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Nerve sparing radical hysterectomy group
- description
- 1. sparing hypogastric nerve 2. sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament 3. sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve
- interventionNames
- Procedure: Nerve sparing radical hysterectomy
- type
- ACTIVE_COMPARATOR
- label
- Radical hysterectomy group
- description
- Conventional radical hysterectomy
- interventionNames
- Procedure: Nerve sparing radical hysterectomy
Primary outcomes (1)
- measure
- Incidence of bladder dysfunction after surgery
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically diagnosed cervical cancer * FIGO stage IA2-IIA * Diameter of tumor is less than 4cm on exam * One of hitological type written below squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma * Age between 18-70 * Performance status; GOG 0-1 * Normal hematological, hepatic, nephrologic function WBC ≥ 4000 cells/mm3 Platelet ≥ 100,000 /mm3 Hemoglobin ≥ 8.0 gm/dL Serum creatinin ≤ 1.3 mg/dL Serum bilirubin ≤ 1.5 mg/dL SBOT/SGPT and Alkaline phoaphatase \< normal X 3 * Patient with informed consent Exclusion creteria: * Small cell carcinoma * Unable to perform surgery because of severe underlying medical disease severe heart disease, congestive heart failure/severe pulmonary disease, pulmonary failure/ active bacterial infectio which needs non oral antibiotic therapy/ associated with other severe medical diseases * Prior chemotherapy or radiotherapy * Severe bladder funtion abnormality * Double primary malignant tumor * Psychiatric problems * Pregnant or breast feeding status * Legally unable to participate clinical trial * When there is a Doctor's decision that patient is unable to participate clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.